Shilpa Medicare Limited is a well-known company that manufactures and supplies affordable API and formulations in a variety of regulated industries.
On August 14, 2025, the share price of Shilpa Medicare (NSE: SHILPAMED) wrapped up at Rs 909.90, indicating a modest gain of 0.41% from its previous close. With a 52-week trading range that includes a low of Rs 555 and a high of Rs 1,000, the stock has been extremely volatile. However, since the Board announced bonus shares and dividend with back-to-back record dates in September, the company has drawn interest from investors searching for pharmaceutical stocks with rewards.
Shilpa Medicare Bonus Shares
“Pursuant to Regulation 30 and 42 read with Schedule III of the SEBI (LODR) Regulations, 2015, as amended it is hereby informed that the Board of Directors in its meeting held on 13th August, 2025 have inter alia considered and recommended the Issue of Bonus equity shares by capitalizing a sum of Rs. 9,77,90,908 (Rupees Nine Crores SeventySeven Lakhs Ninety Thousand Nine hundred and eight only) out of the Company’s securities premium account in the ratio 1:1 i.e. 1 (One) equity share of Rs. 1/- each for every 1 (One) full paid-up equity share of Rs. 1/- each held by the Shareholders of the Company as on the Record Date, subject to the approval of Shareholders in the ensuing AGM. The paid-up capital as on date is Rs. 9,77,90,908 and post bonus issue (upon the members approval in the ensuing AGM) would be increased to Rs. 19,55,81,816. The estimated date by which such bonus shares would be credited/dispatched is within two months of declaration of Bonus shares. Record date for Bonus Shares: – The record date for determining the entitlement of Members of the Company to receive Bonus Equity shares is Friday, 26th September, 2025,” said Shilpa Medicare in a stock exchange filing.
Shilpa Medicare Dividend
“This is further to our intimation dated May 26, 2025, wherein it was informed that the Board of Directors of the Company had, inter alia, recommended a final dividend for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting (AGM). In this connection, pursuant to Regulation 42 of the SEBI (LODR) Regulations, 2015, it is hereby informed that the Record Date has been fixed as Wednesday, 17 September 2025, for determining the entitlement of shareholders to the final dividend. The final dividend, if approved by the shareholders at the ensuing AGM (scheduled to be held on 23rd September 2025), will be paid/dispatched within the statutory time limit from the date of approval,” Shilpa Medicare further informed stock exchanges on Wednesday.
For FY 2024-2025, the Board has decided to pay a dividend of Re. 1.00/- (100%) per equity share with a face value of Rs. 1/-each.
Shilpa Medicare Financials
The company had strong operational performance in the first quarter of FY26, delivering its highest-ever quarterly EBITDA. Despite a 3% sequential dip from Rs 338 crore in 4Q FY25, the total revenue of Rs 328 crore was up 9% year-on-year (YoY) from Rs 302 crore due to robust growth in the API and biologics verticals. The gross profit margin increased by 700 basis points to 76% during the quarter under review, while the gross profit jumped 19% YoY to Rs 248 crore.
EBITDA for the June 2025 quarter was Rs 98 crore, up 17% QoQ from Rs 84 crore reported in the March 2025 or Q4FY25 quarter and 18% YoY from Rs 83 crore reported in the June 2024 quarter. The EBITDA margin improved to 30% from 27% last year and 25% in the previous quarter. Profit after tax (PAT) improved 42% sequentially from Rs 33 crore to Rs 47 crore in Q1FY26, up 236% YoY from Rs 14 crore in Q1FY25. The PAT margin jumped significantly to 14% from 5% in the year-ago quarter and 10% in the fourth quarter of FY25.
“The first quarter of FY26 demonstrated steady progress and strong execution of our strategic priorities. Our partner successfully launched our second NDA in the U.S.-Bortezomib RTU- reinforcing our R&D-driven approach and delivering differentiated products that enhance ease of administration. Pemetrexed also gained momentum in the U.S., while Nilotinib continued to expand its presence in the EU. Additionally, we achieved a historic milestone with NorUDCA’s approval, making Shilpa the first global company approved for NAFLD treatment. These approvals, along with our robust NDA pipeline, positions us for sustained future growth,” said Mr. Vishnukant Bhutada – Managing Director of Shilpa Medicare.
“Our API division(including captive) has reported growth ~25% YoY basis. New product launches, CDMO expansion, expanded capacities, and an improved product mix favoring regulated markets is expected to drive further growth for FY26. In Biologics, our strategic investment in Alveolus Bio accelerates innovation and solidifies Shilpa’s position as a global biotech enabler-bridging cutting-edge science with scalable solutions. Our Novel Biological Entities (NBEs), developed in collaboration with mAbTree and Alveolus, remain on track for Phase I human trials in FY27. On the biosimilar front, Aflibercept has advanced to Phase III clinical trials in India, while Nivolumab has completed PCT, with Phase I trials expected to commence by the end of FY26. We have also received the initial milestone payment for Recombinant Human Albumin from Orion Corporation, and the program is progressing as planned,” Mr. Vishnukant Bhutada added.
“On the regulatory front, we continue to achieve key accreditations for our facilities. During the quarter, Unit VI at Dabaspet, Karnataka-equipped with ODF & TDP manufacturing capabilitiesreceived an EIR from the US FDA. This milestone will support the monetization of our differentiated product portfolio in the US market. Our focus remains on optimizing asset utilization across key verticals, and we are confident in delivering improved profitability in FY26,” he further commented.
Shilpa Medicare Target Price
“Shilpa Medicare (₹912) is maintaining a positive short-term outlook, supported by sustained buying interest and strong price action. The stock is trading well above its key moving averages, reflecting underlying strength. Immediate resistance is placed at ₹940, and a breakout above this level could open the way towards ₹980-₹1,000 in the near term. On the downside, support rests at ₹880, which should act as a cushion for any corrective dips. Momentum indicators suggest continued bullish bias, and traders can consider buying on declines towards the ₹890-₹900 range with a stop-loss below ₹880 for a favorable risk-reward setup,” commented Riyank Arora, technical analyst at Mehta Equities Ltd.
“Shilpa Medicare stock price is slightly bearish on the Daily charts with strong resistance at 950. A Daily close below support of 906 could lead to a target of 820 in the near term,” commented A R Ramachandran, independent research analyst.